Transcript Slide 1

NIH Blueprint Neurotherapeutics
Grand Challenge
New Drugs for Nervous System Disorders
Blueprint NeuRx Strategy
Academia
• Novel drug targets
• Strong disease assays, models
Leverage Strengths of
Academia & Industry
Industry
• Drug development expertise
• Drug development resources
Blueprint NeuRx Scope
Target ID
Assay
Screening
Proof
of
Concept
Lead
Optimization
Investigator-Initiated
Projects
Candidate
Selection
Pre-clinical
Safety
Clinical
Trials
Licensing
Opportunities
Blueprint Neurotherapeutics
Hit
Compound
Phase I
Clinical
Success
“Virtual Pharma” Model
Lead Development Team
Principal investigator *
Industry consultants
NIH staff
Bioactivity/
Efficacy
Studies
Medicinal
Chemistry
Service
PK/Tox
Service
GMP/
Formulation
Services
Ph 1
Clinical
Service
* PI Retains IP
April 2010 RFA: Who Should Apply?
Applicants should have:
• Compound(s) with strong evidence of bioactivity
• Disease assay suitable for medicinal chemistry
• Secondary disease assays and models
Success applicants will receive:
• Funding for bioactivity and efficacy studies
• Access to industry-standard services, consultants
Contact us: [email protected]
[email protected]